April 11, 2021
Business News

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer


BEIJING & CAMBRIDGE, Mass.–()–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that a supplemental Biologics License Application (sBLA) for anti-PD1 antibody tislelizumab was accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for treatment in the second- or third-line setting of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior platinum-based chemotherapy.

“We are excited to submit the third marketing application for tislelizumab from its broad program in lung cancer…



Click here to view the original article.

Related Posts

You might also like ...

Article feature image
CEOs Plan New Push on Voting Legislation – The Wall Street Journal
Article feature image
Routes: New Calif. airline, Alaska lounge at SFO, more OAK routes, Hawaii rule changes, more – SF Gate
Article feature image
Student loan forgiveness: What $10,000 in cancellation would look like by U.S. state